Oral Contraceptive Side Effects Differ by Progestin Formulation, Study Finds
A study using FAERS and MEPS data found that oral contraceptive side effects such as acne, migraine, anxiety, and depression vary by progestin type. Drospirenone-containing pills had higher reported rates of all four, while acne was also greater with levonorgestrel and norgestimate.
A new analysis of U.S. adverse-event and prescribing data indicates that rates of dermatologic and neuropsychological side effects may differ across oral contraceptive formulations. Researchers analyzed reports from the FDA Adverse Event Reporting System (FAERS) and prescription data from the Medical Expenditure Panel Survey to compare reported rates of acne, migraine, anxiety, and depression among users of commonly prescribed oral contraceptives between 2016 and 2020.
The study used ethinyl estradiol/norethindrone as the reference formulation, as it is among the earliest and most widely prescribed combined oral contraceptives. Reported side effect rates were compared across formulations containing different progestins, including levonorgestrel, desogestrel, norgestimate, and drospirenone, as well as a norethindrone-only pill.
Pills containing drospirenone were associated with higher reported rates of acne, migraine, depression, and anxiety. Acne reporting was also greater with levonorgestrel and norgestimate pills, and anxiety was greater with levonorgestrel combination pills and norethindrone alone. Overall, reported depression rates were low across most formulations, but drospirenone-containing pills showed higher reporting. Drospirenone-containing contraceptives were also linked to higher reported rates of migraine and depression.
The authors noted that interpretation of these patterns may be complicated by prescribing trends, including the possibility that certain formulations are preferentially prescribed to patients with specific baseline conditions. Because the analysis relied on post-marketing adverse-event reports, the findings reflect patterns in reported symptoms rather than confirmed causal relationships. The databases also lacked detailed clinical information, preventing adjustment for factors such as patient demographics, dosing differences, or underlying health conditions.
The study, published in the Open Access Journal of Contraception, suggests that a better understanding of formulation-specific side-effect patterns may help clinicians tailor contraceptive selection for patients with dermatologic or mental health comorbidities.